Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Alvotech (NASDAQ:ALVO), A SPAC III Acquisition (NASDAQ:ASPC)

Core Viewpoint - Mereo BioPharma Group's shares plummeted significantly after the announcement that its Phase 3 studies for setrusumab in Osteogenesis Imperfecta did not meet primary endpoints, leading to a broader impact on related stocks in pre-market trading [1][3]. Company Performance - Mereo BioPharma Group shares fell 87.5% to $0.29 in pre-market trading following the disappointing study results [2]. - Ultragenyx Pharmaceutical Inc shares dropped 43.7% to $19.26 as a result of the same study outcomes [3]. - A SPAC III Acquisition Corp shares decreased by 11.7% to $21.21 after a significant rise of 79% on the previous Friday [3]. - Sellas Life Sciences Group Inc shares fell 7.6% to $2.65 after providing an update on its Phase 3 REGAL trial [3]. - Alvotech SA shares dipped 6.8% to $4.90 in pre-market trading [3]. - Sigma Lithium Corp shares tumbled 5.5% to $13.70 after a prior gain of 7% [3].